INCHEON, Korea, June 09, 2025--Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and commercialization agreement with NIPRO ...

Samsung Bioepis has entered into a license, development and commercialization agreement with NIPRO for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan.

Samsung Bioepis (President and CEO: Kyung-Ah Kim) has entered into a license, development and commercialization agreement with NIPRO Corporation (President: Yoshihiko Sano) for multiple biosimilar ...